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Background:  Update of cardiac I-123 metaiodobenzylguanidine (MIBG) imaging improve the prediction of clinical outcome in patients with 
chronic heart failure (CHF). But,renal dysfunction has been observed as abnormal washout of cardiac MIBG imaging. We tried to prospectively 
evaluate the prognostic value of update of cardiac MIBG imaging in CHF, relating to renal dysfunction.
Methods:  In 106 CHF outpatients with radionuclide LVEF < 40% (30±7%), the cardiac MIBG washout rate (WR) was obtained at the entry and 
repeated every year after the entry for three years. Glomerular filtration rate (GFR) was calculated by the Modification of Diet in Renal Disease 
equation at the entry, and these patients were divided into two groups, patients with and without chronic kidney disease (CKD:GFR<60ml/
min/1.73m2). The primary endpoint was defined as hospitalization of heart failure worsening and sudden death.
Results:  At the entry, 48 of 106 patients had CKD. The incidence of abnormal WR (>27%) was greater in patients with than without CKD 
(58%(28/48) vs 41%(24/58), p=0.08). For a mean follow-up of 7.5±4.0 years, 46 patients had the primary endpoint (hospitalization of heart failure 
worsening in 23 and sudden death in 23 patients). At multivariate Cox analysis, WR was a significant predictor of poor outcome in patients both with 
(P=0.037) and without (P=0.012) CKD. Patients with abnormal WR at the entry had a higher morbidity than those without abnormal WR in patients 
both with (68% vs 20%, p=0.0016) and without (58% vs 26%, p=0.0021) CKD. At the last evaluation of MIBG study, the poor outcome was much 
more frequently observed in patients with than without abnormal WR, irrespective of the presence of CKD (with CKD: 70% vs 12%, p=0.0003, without 
CKD: 68% vs 22%, p<0.0001). The hazard ratios of abnormal WR at the last evaluation for poor outcome in patients with and without CKD was 9.3 
(95%CI 2.2-39.8) and 5.0 (95%CI 2.0-18.2), respectively, which were greater than those of abnormal WR at the entry (4.9(95%CI 1.6-14.4) and 
3.5(95%CI 1.7-13.7), respectively).
Conclusions:  Update of cardiac MIBG imaging would improve the prediction of poor outcome in CHF patients, irrespective of the presence of CKD.
